Eli Lilly
Novo diabetes drug outperforms Lilly rival at Phase 3
August 17, 2017Research and Development Eli Lilly, Novo Nordisk, diabetes, life sciences, medicine, pharma, pharmaceutical, type 2 diabetes
Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …
Lilly snaps up autoimmune drug in $400m biotech partnership
July 25, 2017Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Nektar, aceutical, biotech, drugs, healthcare, phar, pharma
Eli Lilly is to enter a partnership with Nektar Therapeutics to tap into the biotech’s new autoimmune disease therapy as …
Eli Lilly arthritis drug outperforms Humira and receives NICE backing
June 30, 2017Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis
Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …
FDA fast-tracks Pfizer and Lilly’s chronic pain drug
June 15, 2017Research and Development, Sales and Marketing Eli Lilly, FDA, Pfizer
Pfizer and Eli Lilly are celebrating the FDA’s decision to grant fast-track designation to their joint venture tanezumab in the …
Lilly bolsters diabetes assets with $55m KeyBioscience deal
June 9, 2017Medical Communications, Sales and Marketing Eli Lilly, KeyBiosciences
Eli Lilly has announced a strategic collaboration with KeyBioscience that sees the former company gain access to develop and commercialise …
EMA’s CHMP recommends Sanofi’s Humalog biosimilar
May 22, 2017Manufacturing and Production, Sales and Marketing Eli Lilly, Humalog, Sanofi
Sanofi has received a positive recommendation by the CHMP for its biosimilar to Eli Lilly’s Humalog. The recommendation for approval …
Lilly’s migraine drug succeeds in Phase 3 trials
May 15, 2017Research and Development, Sales and Marketing Eli Lilly, migraines
Eli Lilly announced the successful results of three Phase 3 trials examining the benefits of its drug, galcanezumab, in patients …
Lilly promises $850 million investment in message to White House
March 27, 2017Manufacturing and Production, Sales and Marketing Eli Lilly, President trump, lilly
Eli Lilly’s latest press release indicated that it would be spending $850 million in developing its worldwide US operations, particularly …
Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
March 21, 2017Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …
Lilly’s breast cancer drug meets primary endpoint
March 21, 2017Manufacturing and Production, Research and Development CDK 4/6 inhibitors, Eli Lilly, abemaciclib
Eli Lilly has announced that its trial of abemaciclib, in combination with fulvestrant, had met its primary endpoint of progression-free …
Lilly €200m expansion of Cork site under review
February 13, 2017Manufacturing and Production, Sales and Marketing Eli Lilly, Ireland, cork
Eli Lilly’s planned €200m investment to its manufacturing plant in Kindsdale, County Cork, is now under-review. The expansion would bring …
Trump meets with top pharma execs, reiterates pledge to lower “astronomical” prices
January 31, 2017Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Eli Lilly, Novartis, PhRMA, Trump
President Trump convened with a number of top pharma execs at the White House on Tuesday to discuss the key …
Price-fixing class action lawsuit levelled at three major insulin producers
January 31, 2017Manufacturing and Production, Sales and Marketing Eli Lilly, Novo Nordisk, Sanofi, diabetes, insulin, price-fixing
A group of patients has filed a class action lawsuit in a federal court in Massachusetts, accusing three companies of …
Major pharma firms join Liverpool Uni in £14m pharmacovigilance project
January 30, 2017Research and Development, Sales and Marketing AZ, AbbVie, Eli Lilly, GSK, University of Liverpool, pharmacovigilance
The UK’s University of Liverpool is to launch a £14 million pharmacovigilance project focused on using new modelling approaches to …
Lilly brings migraine drug home with $960m acquisition
January 19, 2017Sales and Marketing CoLucid Pharmaceuticals, Eli Lilly
Eli Lilly has announced it is to shell out $960 million to snatch up CoLucid Pharmaceuticals and specifically its migraine …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
